Inclusion Criteria:  Age ≥ 18 years; Histologically proven colorectal liver metastasis； With liver-dominant disease； Primarily evaluated as potentially resectable and conversed successfully Adequate hematologic function: absolute neutrophil count (ANC)≥1.5×109/l, platelets≥75×109/l, and international normalized ratio (INR) ≤1.3 (within 1 week prior to randomization) Adequate liver and renal function: total bilirubin ≤2.0 mg/dl, alanine aminotransferase, aspartate aminotransferase ≤ 5x upper limit of normal, and albumin≥2.5 g/dl, serum creatinine≤2.0 mg/dl (within 1 week prior to randomization); Written informed consent for participation in the trial.  Exclusion Criteria:  Primarily evaluated as resectable Failed to converse Patients with known hypersensitivity reactions to any of the components of the study treatments. Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding Other previous malignancy within 5 years Known drug abuse/ alcohol abuse Legal incapacity or limited legal capacity